Capricor Therapeutics is a leading biotechnology company focused on developing new treatments for diseases. On May 15, 2026, Roth Capital analyst Boobalan Pachaiyappan lowered the price target for Capricor Therapeutics to $38.00. This new target still represents a potential 27.47% upside from the stock's price of $29.81 at the time.
The analyst's valuation comes as Capricor Therapeutics awaits a key decision. Its main therapy candidate, deramiocel, a promising Duchenne muscular dystrophy treatment, is under active review by the FDA. The company has a PDUFA target action date of August 22, 2026. This is the deadline by which the FDA aims to decide on the drug's approval, a critical moment for biotech investment.
This period is what CEO Linda Marbán calls “a truly defining moment.” Capricor Therapeutics is preparing to commercialize deramiocel on its own. This strategic shift follows a legal dispute with its distribution partner, NS Pharma, over the product's pricing structure. Capricor Therapeutics has filed a lawsuit to cancel the agreement, highlighting the complexities of drug development and commercialization.
Financially, Capricor Therapeutics appears stable, with a robust cash balance of approximately $279.00 million. This funding is expected to support its operations into the fourth quarter of 2027, providing a solid foundation for future growth. The company is also expanding its manufacturing facility and expects a new Chief Commercial Officer to join soon, signaling readiness for potential FDA approval and market entry.
Upon successful FDA approval, Capricor Therapeutics may receive a Priority Review Voucher. This valuable voucher can be sold to other companies for a significant sum, providing crucial capital without issuing new stock, which would dilute the value of existing shares. The Capricor Therapeutics stock has a 52-week range between $4.30 and $40.37 and a market capitalization of $1.36 billion, reflecting its position in the biotech market.
